drugset / Press release
Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
2022-12-21 · Moleculin Biotech, Inc. · original moleculin.com ↗
– Ongoing efforts to open additional clinical sites in Poland and to gain approval to proceed in other European countries
The release as fetched from its publisher. moleculin.com ↗